// App-Quantinova.ai

: First description of De Novo Inflammatory Bowel Disease (IBD in two adolescent patients after lung transplant (LTX

Researchers

Presenter

  • Doxa Kotzia

Principal Investigators

  • Fevronia Kiparissi

  • Helen Spencer

Medical Centers

  • INIVATA, Cambridge, United Kingdom

  • NCRI, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Gastroenterology (GU)

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

  • Other

  • Genetic Disorder

Disease

  • Inflammatory bowel disease

  • Acute cellular rejection

  • Pulmonary alveolar proteinosis

  • Ulcerative colitis

  • Post-transplant lymphoproliferative disorder

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab

  • Budesonide

  • Rituximab

  • Protein C

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved